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Systemic inf lammation (SI) is involved in the pathogenesis of acute decompensation (AD) and acute-on-chronic liver 
failure (ACLF) in cirrhosis. In other diseases, SI activates tryptophan (Trp) degradation through the kynurenine 
pathway (KP), giving rise to metabolites that contribute to multiorgan/system damage and immunosuppression. In 
the current study, we aimed to characterize the KP in patients with cirrhosis, in whom this pathway is poorly 
known. The serum levels of Trp, key KP metabolites (kynurenine and kynurenic and quinolinic acids), and cy-
tokines (SI markers) were measured at enrollment in 40 healthy subjects, 39 patients with compensated cirrhosis, 
342 with AD (no ACLF) and 180 with ACLF, and repeated in 258 patients during the 28-day follow-up. Urine KP 
metabolites were measured in 50 patients with ACLF. Serum KP activity was normal in compensated cirrhosis, in-
creased in AD and further increased in ACLF, in parallel with SI; it was remarkably higher in ACLF with kidney 
failure than in ACLF without kidney failure in the absence of differences in urine KP activity and fractional excre-
tion of KP metabolites. The short-term course of AD and ACLF (worsening, improvement, stable) correlated closely 
with follow-up changes in serum KP activity. Among patients with AD at enrollment, those with the highest base-
line KP activity developed ACLF during follow-up. Among patients who had ACLF at enrollment, those with im-
mune suppression and the highest KP activity, both at baseline, developed nosocomial infections during follow-up. 
Finally, higher baseline KP activity independently predicted mortality in patients with AD and ACLF. Conclusion: 
Features of KP activation appear in patients with AD, culminate in patients with ACLF, and may be involved in 
the pathogenesis of ACLF, clinical course, and mortality. (Hepatology 2019;69:1686-1701).
The association of liver failure with extrahe-patic organs/systems dysfunction is a char-acteristic feature of cirrhosis that affects morbidity and mortality. In fact, acute-on-chronic liver failure (ACLF), which is characterized by sys-temic inflammation (SI) and single or multiple (≥ 2) 
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organ failures, is the main cause of death in cirrho-
sis.(1) The traditional paradigm of extrahepatic organ 
failure in cirrhosis relies on two principles: (1) They 
are functional disorders and (2) the pathogenesis is 
specific for each organ failure. However, this para-
digm is changing and research has proven that SI and 
oxidative stress, which are well-known mechanisms 
of multiorgan failure in other clinical conditions, may 
be the common link between the diseased liver and 
extrahepatic organ failure in cirrhosis.(2) Patients with 
decompensated cirrhosis exhibit chronic SI, possibly 
in relation to sustained intestinal bacterial translo-
cation. In contrast, ACLF develops in the setting of 
further increase of SI promoted by precipitating fac-
tors (e.g., bacterial infections). Moreover, significant 
parenchymal renal and cerebral lesions and inflam-
matory changes have been described in kidney biop-
sies, brain autopsies, and imaging studies in patients 
with cirrhosis and experimental animals with renal 
failure or encephalopathy.(3-5) Extrahepatic organ fail-
ure(s) in cirrhosis could therefore be the consequence 
of tissue immunopathology.(6)
SI also affects metabolism and induces changes in a 
myriad of biologically active small molecules. Among 
them, the degradation of tryptophan (Trp) through 
the kynurenine pathway (KP) to Trp-kynurenine 
derivatives (Trp-KYN derivatives) is of special interest 
in cirrhosis (Fig. 1).(7-9) The KP is responsible for 95% 
of overall Trp degradation. The first and rate-limited 
step of KP is catalyzed by two enzymes: Tryptophan 
2,3-dioxygenase (TDO) and indoleamine 2,3-diox-
ygenase (IDO).(8,9) The expression of TDO2 (the 
gene-encoding TDO) is biased in the liver. In con-
trast, IDO1 and IDO2 (the genes encoding IDO) are 
predominantly extrahepatic and expressed primarily in 
peripheral blood immune cells, dendritic cells, endo-
thelial cells, macrophages and microglia, astrocytes, 
and epithelial cells (e.g., renal tubular cells).(8,9) Under 
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physiological conditions, most KP metabolites are 
constitutively synthesized within the liver by TDO; 
only a marginal proportion is synthesized outside the 
liver. However, in the setting of SI there is intense 
overexpression of IDO and extrahepatic production 
of Trp-KYN derivatives including kynurenine (KYN, 
which is an endothelial-derived relaxing factor and 
neuroactive molecule), quinolinic acid (QA, which is a 
neuronal N -methyl-d-aspartic acid [NMDA] receptor 
neurotoxic agonist), and kynurenic acid (KA, which 
is a NMDA antagonist). KYN and KA exert immu-
nomodulatory actions by binding to aryl hydrocarbon 
receptor and GPR35 in immune cells.(9,10) In addi-
tion, the KP can produce picolinic acid (a second 
NMDA receptor antagonist), as well as the immuno-
suppressive metabolites 3-hydroxykynurenine (3-HK) 
and 3-hydroxyanthranilic acid (3-HAA).(7-9) Finally, 
during KP activation, there is increased generation 
of highly reactive oxygen and nitrogen species, which 
contribute to immunopathology. IDO expression can 
be increased by interferon γ, tumor necrosis factor α 
(TNFα), and other cytokines.
Circulating Trp can be transported across the cell 
membrane and the blood–brain barrier (BBB) only in 
FIg. 1. Trp-KP metabolic pathway including potential stimuli of TDO and IDO. Numbers indicate the enzymes participating in 
each biosynthetic step: 1 = formamidase; 2 = kynurenine aminotransferase; 3 = kynurenine 3-monooxygenase; 4 = kynureninase; 
5 = anthranilate 3-monooxygenase; 6 = 3-hydroxyanthranilic acid dioxygenase; and 7 = 2-hydroxymuconate-6-semialdehyde 
dehydrogenase. The molecules measured in the study are included in the blue boxes.
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its free form, which represents approximately 5% of 
the total Trp concentration in plasma.(11) The remain-
ing molecules circulate bound to plasma albumin. In 
patients with decompensated cirrhosis, however, free 
Trp in plasma is increased due to hypoalbuminemia, 
structural changes in the albumin molecule, and com-
petition with endogenous and exogenous substances 
for the binding to albumin Sudlow site II,(12) including 
kynurenines. Once within the cells, TDO and IDO 
interact with Trp and initiate the KP. Although the 
complete set of enzymes of the KP is expressed only in 
the liver, kynurenines can cross the cellular membrane 
through L-type amino acid transporter, which is also 
used by Trp, and act in extrahepatic cells as intermedi-
ate substrates for the synthesis of downstream metab-
olites.(13) Metabolites of the KP, therefore, may act as 
autocrine, paracrine, and even as endocrine mediators.
Kynurenines are involved in the pathogenesis of dis-
eases associated with acute and chronic SI, including 
severe sepsis, acute pancreatitis, metabolic syndrome, 
acute confusional states, depression, and chronic neu-
rodegenerative diseases. Because the level of KP acti-
vation is poorly known in cirrhosis, this observational, 
prospective study was aimed to investigate the poten-
tial role of KP activity in acute decompensation (AD) 
and ACLF in cirrhosis.
Experimental Procedures
StUDy popUlatIoN
The study was performed in patients included 
in the CANONIC study, an European multicenter, 
prospective, observational investigation in 1343 con-
secutive patients with cirrhosis hospitalized for the 
treatment of AD. In this study, clinical data and bio 
samples were obtained not only at enrollment (which 
generally coincided with hospital admission), but also 
sequentially during a follow-up period of 28 days.(1)
This study included 342 randomly selected 
patients with AD and 180 with ACLF at enroll-
ment (95 ACLF-1, 65 ACLF-2, and 19 ACLF-3). 
In all patients (n = 522), the serum KP (which is 
mentioned as KP throughout the study) was assessed 
at enrollment and in 258 measurements that were 
repeated at the last hospital visit within the 28-day 
follow-up period. The urine KP was assessed in 50 
patients with ACLF. A detailed description of data 
and sample collection policy in the CANONIC study 
is given in the Supporting Information. A diagram of 
the patients included in the current study is shown in 
Supporting Fig. S1. All patients included have par-
ticipated in other investigations; therefore, many data 
have been reported previously.(14-17)
Thirty-nine additional nonhospitalized patients 
with compensated cirrhosis (no previous history of 
AD) and 40 healthy blood donors (age: 45-65 years) 
were studied as controls. All patients with compen-
sated cirrhosis had clinically significant portal hyper-
tension, as indicated by presence of esophageal varices 
and/or high FibroScan liver stiffness.
Details regarding the institutional research boards 
that approved the CANONIC study and the current 
study are found in the Supporting Information.
MeaSUReMeNt oF trp aND  
trp-KyN DeRIVatIVeS By  
lIQUID CHRoMatogRapHy 
CoUpleD WItH MaSS 
SpeCtRoMetRy
Trp and Trp-KYN derivatives in serum were first 
assessed in the frame of an untargeted liquid chroma-
tography–mass spectrometry (LC-MS)-based metab-
olomics approach. Metabolites were extracted from 
serum samples following methanol-assisted protein 
precipitation. Therefore, detected metabolites were in 
their free state, not bound to albumin and/or other 
proteins. Extracts were analyzed by LC-MS using 
an Ultimate 3000 chromatographic system (Thermo 
Fisher Scientific, Courtaboeuf, France) coupled with 
an Exactive mass spectrometer (Thermo Fisher 
Scientific) fitted with an electrospray source and 
operating in the positive and negative ion modes for 
metabolite separations on C18 and ZIC-pHILIC col-
umns, respectively.(18) The metabolite concentrations 
from the different experimental batches were stan-
dardized using the LOESS algorithm.(19) Absolute 
targeted quantification was performed in 234 ran-
domly selected subset of samples from the whole 
group (16 healthy subjects, 20 patients with compen-
sated cirrhosis, 100 with AD, and 98 with ACLF). 
Serum extracts were injected into a LC-MS/MS sys-
tem consisting of a Waters ACQUITY UPLC sys-
tem (Milford, MA) equipped with an UPLC charged 
surface hybrid column and coupled with a Waters 
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XEVO TQ-XS mass spectrometer operating in the 
positive ion electrospray multiple reaction monitor-
ing mode. Quantification was performed using stan-
dard calibration curves and internal labeled standards 
(d5-L-Trp, 
13C6-L-KYN, d5-KA, and 
13C3,
15N1-QA). 
To explore the renal handling of Trp and KYN deriva-
tives in patients with ACLF, absolute serum and urine 
concentrations were measured by LC-MS/MS in 50 
randomly selected samples from patients with ACLF 
(25 with kidney failure and 25 without kidney failure). 
Plasma and urine creatinine levels were also measured 
by a standard method based on Jaffé’s reaction, and the 
fractional renal excretion of each individual metabolite 
was calculated based on the equation ([urinary Trp-
KYN derivative concentration/serum Trp-KYN deriv-
ative concentration]/[urinary creatinine concentration/
serum creatinine concentration] x 100).  More detailed 
information is given in the Supporting Information.
otHeR MeaSUReMeNtS
assessment of SI and Systemic 
oxidative Stress
SI was assessed by the plasma levels of 17 cytokines 
and the circulating markers of macrophage activa-
tion soluble CD163 (sCD163) and mannose recep-
tor (sMR/sCD206). Oxidative stress was assessed 
through the analysis of the redox state of plasma albu-
min (human nonmercaptalbumin 2 [HNA2]). These 
results have been previously reported.(15,16)
Biomarkers of Systemic Circulatory 
Function
Plasma copeptin concentration (PCC) and plasma 
renin concentration (PRC), which estimate antid-
iuretic hormone release and the activity of the 
renin-angiotensin system, respectively, were selected 
as biomarkers of circulatory function.
assessment of IDO1 and IDO2 gene 
expression in peripheral Blood Cells
IDO1  and IDO2 messenger RNA (mRNA) expres-
sion was determined by real-time PCR in RNA from 
peripheral blood mononuclear cells (PBMCs) isolated 
from healthy volunteers (n = 4) and patients with AD 
cirrhosis (n = 8) (see Supporting Information).
DeFINItIoNS
The following definitions concerning clinical fea-
tures are detailed in the Supporting Information: 
compensated and decompensated cirrhosis, AD, 
ACLF, organ failures including liver failure, kidney 
failure (KF), brain failure (BF), coagulation failure, 
circulatory failure and respiratory failure, kidney dys-
function (KD), brain dysfunction (BD), ACLF grades, 
and clinical courses of AD and ACLF.
StatIStICal aNalySIS
Results are presented as frequency and percent-
age for categorical variables, mean, and SD for nor-
mally distributed continuous variables, and median 
and interquartile range for not normally distributed 
continuous variables. More details are found in the 
Supporting Information.
Results
“BeDSIDe” Data aND “BeNCH” 
ReSUltS INVeStIgatINg 
SySteMIC CIRCUlatoRy 
FUNCtIoN aND SI at 
eNRollMeNt
Age and gender were similar in the three groups 
of patients (compensated cirrhosis, AD, and ACLF) 
(Supporting Table S1). The prevalence of alcoholic 
cirrhosis increased and the prevalence of cirrhosis 
associated with hepatitis C virus (HCV) decreased 
progressively across the three groups of patients with 
cirrhosis. There were significant differences among 
patients with compensated cirrhosis, AD, and ACLF 
in standard liver and renal function tests, platelets, 
C-reactive protein, and white blood count. The most 
frequent complication associated with cirrhosis at 
enrollment in patients with AD and ACLF was asci-
tes, followed by encephalopathy, bacterial infections, 
and gastrointestinal bleeding.
PCC, PRC, and mean arterial pressure (MAP) 
were normal in patients with compensated cirrhosis, 
markedly increased (PCC and PRC) or decreased 
(MAP) in patients with AD, and significantly more 
deteriorated in patients with ACLF (Supporting 
Table S2). PCC, which was more sensitive than PRC 
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in differentiating AD from ACLF, was used for asso-
ciation analysis. The plasma levels of cytokines were 
normal or only moderately increased in patients with 
compensated cirrhosis, markedly elevated in patients 
with AD, and significantly higher in patients with 
ACLF than in patients with AD (Supporting Table 
S2). Plasma sCD163 and sMR/sCD206 levels were 
increased in patients with AD and significantly 
higher in patients with ACLF than in patients with 
AD. Finally, plasma levels of HNA2 were increased 
to a similar degree in patients with compensated and 
decompensated cirrhosis, but significantly higher in 
patients with ACLF.
Kp IS aCtIVateD IN patIeNtS 
WItH aD aND aClF
During the assessment of the whole serum metab-
olome using an untargeted and semi-quantitative 
HRMS-based approach, we detected four major 
components of the KP (Trp, KYN, KA, and QA) at 
sufficiently high levels to permit accurate and reliable 
measurements. KYN, KA, and QA are among the 
most relevant kynurenines and are produced at differ-
ent steps of the KP (Fig. 1). Accordingly, measuring 
the serum levels of these metabolites provides com-
prehensive information on KP activity. In addition, 
the KYN to Trp ratio (KYN/Trp) is used widely to 
estimate the TDO and IDO activity.(20) Table 1A lists 
the serum levels of these metabolites, as measured by 
LC-MS and expressed in relative units corresponding 
to chromatographic peak areas, in healthy controls and 
patients with compensated cirrhosis, AD, and ACLF. 
In patients with compensated cirrhosis, the KP activ-
ity was not significantly different from healthy con-
trols. In contrast, there were major changes in patients 
with AD and ACLF. KYN/Trp (Table 1A) and serum 
levels of KYN, KA, and QA (Table 1A, Fig. 2A) were 
higher, whereas Trp levels were lower (Table 1A, 
Fig. 2B), in patients with AD and ACLF relative 
to patients with compensated cirrhosis and healthy 
controls, which is consistent with increased Trp deg-
radation and enhanced production of kynurenines 
due to overactivity of TDO or IDO. Indeed, mRNA 
expression for both IDO1 and IDO2  was significantly 
up-regulated in PBMC from patients with AD with 
respect to healthy donors (IDO1 : 6.2 ± 2.7 versus 0.40 
± 0.1 arbitrary units [a.u.], P  < 0.05; IDO2: 1.9 ± 0.5 
versus 0.3 ± 0.2 a.u., P  < 0.03). Interestingly, patients 
with ACLF had the lowest levels of Trp, and the 
highest KYN/Trp and serum levels of KYN, KA, and 
QA. KA and QA were the most sensitive markers of 
KP activation in our patients, and therefore were used 
thereafter for most association analyses.
Table 1B indicates that these differences in the 
serum levels of Trp and selected Trp-KYN derivatives 
between groups were similarly observed in the sub-
set of 218 patients in whom absolute concentrations 
were measured using synthetic standards during the 
LC-MS analysis. All values detected in the serum 
were within the ng/mL to µg/mL range. The correla-
tion coefficients between both types of measurements 
were Trp: r = 0.91; KYN: r = 0.77; KA: r = 0.87; QA: 
r = 0.93; P  < 0.0001 for all.
Kp aCtIVatIoN CoRRelateS 
WItH SI INteNSIty
There were significant but weak positive correla-
tions between inflammatory mediators and serum 
levels of KA and QA in the whole series of patients 
(Supporting Table S3), suggesting an association 
among SI, IDO, and KP overactivity. The strongest 
association was observed between QA and TNFα 
(Fig. 2C).
Kp aCtIVIty aND oVeRall 
SeVeRIty oF CIRRHoSIS HaVe 
SIMIlaR oRCHeStRatIoN
KP overactivity is associated with impairment of 
systemic circulatory function. Although KP activity 
rose progressively across patient groups of increas-
ing severity (Table 1A), there were parallel progres-
sive decline in MAP and increase in PCC and PRC 
(Supporting Table S2). Moreover, KA and QA lev-
els had significant direct correlations with PCC (r = 
0.39; P  < 0.001 and r = 0.48; P  < 0.001, respectively). 
Together these findings show a positive correlation 
between the intensity of impairment in circulatory 
function and the KP activity.
Hierarchization of the Kp activity 
according to the existence of Kidney or 
Brain Failure or Dysfunction
Among patients with ACLF at enrollment, 
those who had kidney failure (ACLF-KF) exhibited 
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lower baseline serum levels of Trp and higher KYN, 
KA, and QA than those who had KF-free ACLF 
(Table 1C, Fig. 2A,B). These data indicate that KP 
overactivity is more marked in patients with KF than 
in those who had an ACLF form defined by the 
presence of extrarenal organ failures. Of note, the 
serum levels of KA and QA were higher in patients 
with KF-free ACLF than in those with AD, indicat-
ing that KF-free ACLF is also associated with KP 
overactivity, although to a lesser degree than in the 
case of ACLF-KF. Interestingly, among patients with 
AD, there was higher KP activity in patients with 
KD relative to patients free of both kidney and brain 
dysfunctions (Table 1D), indicating that KP overac-
tivity is also higher in patients with AD and KD than 
in those without KD.
We performed additional analyses to explore the 
intrarenal handling of KP metabolites in the context 
of ACLF. For this, we measured the serum and urine 
creatinine and absolute serum and urine Trp and KYN, 
KA, and QA concentrations and the renal fractional 
excretion of these metabolites in 25 patients with 
ACLF-KF and 25 with KF-free ACLF (Table 2). In 
agreement with our first results expressed in relative 
units (Table 2), the results of additional experiments 
confirmed that the absolute serum concentrations 
taBle 1. Metabolites of the Kynurenine pathway at enrollment, across Different groups of Individuals
Groups of individuals Tryptophan (Trp) Kynurenine (KYN) KYN/Trp ratio Kynurenic acid Quinolinic acid
A. All study individuals Median values for metabolites of the KYN pathway (IQR) — arbitrary units corresponding to peak area/5×10 4
Healthy subjects (n = 40) 469 (390-590) 6.4 (3.6-8.0) 0.012 (0.008-0.016) 0.64 (0.50-0.89) 11.1 (7.7-28.9)
Compensated cirrhosis (n = 39) 512 (429-554) 7.7 (6.2-25.5) 0.017 (0.012-0.050) 0.82 (0.46-1.00) 11.8 (7.7-22.9)
AD (n = 337) 372 (255-527) 9.8 (5.8-21.6) 0.026 (0.014-0.061) 0.86 (0.49-1.44) 24.5 (16.0-47.2)
ACLF (n = 180) 353 (240-489) 15.2 (7.5-28.3) 0.038 (0.022-0.092) 2.26 (1.06-6.66) 96.2 (30.2-184.4)
P value <0.001 <0.001 <0.001 <0.001 <0.001
B. Subsets of study individuals Median values for metabolites of the KP (IQR) (µg/mL) 
Healthy subjects (n = 16) 10.45 (9.37-13.37) 0.32 (0.26-0.37) 0.026 (0.024-0.034) 0.0048 (0.0042-0.0059) 0.046 (0.042-0.052)
Compensated cirrhosis (n = 20) 12.82 (11.47-14.20) 0.51 (0.46-0.66) 0.047 (0.033-0.054) 0.006 (0.05-0.0081) 0.083 (0.056-0.12)
AD (n = 100) 9.48 (6.37-13.83) 0.49 (0.35-0.61) 0.049 (0.039-0.068) 0.007 (0.004-0.01) 0.15 (0.08-0.24)
ACLF (n = 98) 8.96 (6.48-11.81) 0.75 (0.53-0.98) 0.081 (0.061-0.113) 0.018 (0.009-0.039) 0.42 (0.17-0.79)
P value 0.0016 <0.001 <0.001 <0.001 <0.001
Median values for metabolites of the KYN pathway (IQR) — arbitrary units corresponding to peak area/5×10 4
C. Patients with either AD, ACLF-KF, or 
KF-free ACLF
AD (n = 337) 372 (255-527) 9.8 (5.8-21.6) 0.026 (0.014-0.061) 0.86 (0.49-1.44) 24.5 (16.0-47.2)
KF-free ACLF (n = 76) 381 (250-562) 9.9 (5.6-19.1) 0.025 (0.013-0.049) 1.14 (0.50-2.29) 39.9 (22.2-105.1)
ACLF-KF (n = 103) 332 (224-435) 19.5 (11.3-35.1) 0.057 (0.030-0.119) 4.82 (1.99-11.92) 131.2 (70.5-255.3)
P value 0.050 <0.001 <0.001 <0.001 <0.001
D. Patients with AD according to the 
presence or absence of brain dysfunc-
tion (BD) or kidney dysfunction (KD)
No BD/No KD (n = 209) 376 (258-541) 8.2 (5.2-16.3) 0.021 (0.013-0.046) 0.68 (0.43-1.07) 21.1 (13.4-40.3)
BD (n = 60) 411 (293-549) 13.9 (7.4-31.8) 0.032 (0.015-0.086) 0.99 (0.63-1.54) 26.8 (18.3-43.1)
KD (n = 38) 337 (198-437) 16.6 (9.7-28.9) 0.050 (0.025-0.091) 1.89 (1.27-3.06) 55.8 (31.6-99.5)
BD and KD (n = 21) 316 (298-436) 21.7 (6.9-36.8) 0.050 (0.023-0.109) 1.51 (0.73-2.30) 45.6 (20.1-77.0)
P value 0.291 <0.001 <0.001 <0.001 <0.001
E. Patients stratified according to their 
clinical course by 28 days
AD throughout the study (n = 281) 376 (253-541) 9.6 (5.6-21.1) 0.025 (0.014-0.059) 0.79 (0.46-1.28) 23.4 (15.6-44.6)
Development of KF-free ACLF (n = 23) 383 (312-507) 10.7 (5.8-16.9) 0.022 (0.012-0.062) 1.11 (0.60-1.67) 31.3 (16.4-48.2)
Development of ACLF-KF (n = 33) 332 (258-443) 12.1 (7.1-29.4) 0.042 (0.021-0.091) 1.48 (0.88-2.25) 45.6 (20.6-97.2)
P value 0.452 0.154 0.045 0.001 <0.001
Note: P values are from the overall comparisons.
AD denotes acute decompensation; KF, kidney failure; ACLF-KF, ACLF associated with KF; KF-free ACLF, ACLF not associated 
with KF.
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of KYN, KA, and QA were increased significantly 
in patients with KF-ACLF as compared with those 
with KF-free ACLF. In contrast, the urinary concen-
tration and the fractional urinary excretion of these 
Trp-KYN metabolites were similar in the two groups 
of patients (Table 2). There was yet marked heteroge-
neity in the urine-to-serum ratio of the levels of each 
Trp-KYN metabolite, within each group of patients. 
For example, although the urine-to-serum ratios for 
KA concentrations was +472 and +88 in patients with 
KF-free ACLF and those with ACLF-KF, respec-
tively, the ratios were lower for QA (+116 and +19, 
respectively) or even much lower for KYN (+3.3 and 
− 0.66 fold, respectively). The urine concentration of 
Trp was markedly lower in patients with ACLF-KF 
than in patient with KF-free ACLF.
There were also close associations between KP 
overactivity and hepatic encephalopathy. Most patients 
(36 of 43 patients) with BF had ACLF, and therefore 
very high levels of KA (1.82 [0.90-4.39] a.u.) and QA 
(67.2 [26.5-156.6] a.u.). The serum levels of KA and 
QA were also higher in the 60 patients with AD and 
BD alone than in the 209 patients without KD and/
or BD (Table 1D).
FIg. 2. (A) Serum levels of QA at enrollment in healthy subjects (H) and patients with compensated cirrhosis (C), AD, and ACLF 
without and with kidney failure (No KF and KF), respectively. (B) Serum levels of Trp at enrollment in healthy subjects (H) and 
patients with compensated cirrhosis (C), AD, and ACLF without and with kidney failure (No KF and KF, respectively). (C) Correlation 
between QA and TNFα. (D) Serum levels of QA at enrollment in healthy subjects (H), patients with compensated cirrhosis (C), 
patients with AD throughout the study, and patients with baseline AD who developed ACLF without and with kidney failure (No KF 
and KF, respectively) during follow-up. The values in (A) and (D) are represented in quadratic scale and in (C) in natural logarithmic 
scale. Because the serum levels of QA were similar in healthy subjects and compensated cirrhosis, statistical comparison among groups 
in (A), (B), and (D) were performed between the groups of patients with cirrhosis. *P  < 0.05; **P  < 0.001. Values in the metabolites of 
the KP are in arbitrary units corresponding to peak area/5 × 104.
Hepatology, april 2019CLÁRIA, MOREAU, ET AL.
1694
Together these findings indicate that, in patients 
with AD and in those with ACLF, the degree of KP 
activation is related closely to the presence of alterations 
in kidney and brain functions, and to their intensities.
Kp overactivity Is Higher in patients 
With ongoing Bacterial Infections 
than in those Without
As expected, plasma cytokines(16) and markers of 
KP activity (serum levels of KA and QA) were sig-
nificantly higher in patients with bacterial infections 
at enrollment than in patients without, both in the 
whole series of patients (Supporting Table S4) and 
among patients with ACLF (Supporting Table S5).
Different Clinical Courses of aD and 
aClF are associated With Distinct 
profiles of Kp activity
There was a close association between changes in 
the serum levels of KA and QA and the 28-day fol-
low-up clinical course of patients with AD and ACLF 
(Table 3). Improvement of ACLF (36 patients with 
ACLF-1, 30 with ACLF-2, and 3 with ACLF-3) 
and worsening of AD or ACLF (25 patients with 
no ACLF, 10 with ACLF-1, and 11 with ACLF-2) 
were associated with parallel changes in the serum 
levels of KA and QA. Patients with AD steady course 
and those with ACLF steady course (22 patients had 
ACLF-1, 15 had ACLF-2, and 11 had ACLF-3) did 
not present significant changes in the serum levels of 
KA and QA during the 28-day follow-up.
aNteCeDeNCe oF INCReaSeD 
Kp aCtIVIty RelatIVe to tHe 
DeVelopMeNt oF aClF
Among the 337 patients with AD at enroll-
ment, those who developed ACLF-KF during the 
28-day follow-up period had higher baseline KA 
and QA concentrations than those who developed 
KF-free ACLF (Table 1E, Fig. 2D). The base-
line concentrations of these kynurenines were also 
higher in patients developing KF-free ACLF rela-
tive to patients without ACLF throughout the study 
(Table 1, Fig. 2D), although differences were not 
statistically significant. Our findings therefore show 
an antecedence of an increase in KP activity relative 
to the development of ACLF-KF.
taBle 2. Serum and Urine Concentrations of tryptophan, Kynurenine, Kynurenic acid, and Quinolinic acid in patients 
with aClF, according to the presence or absence of Kidney Failure
Variable
No Kidney Failure Kidney Failure
P-value(N = 25) (N = 25)
Serum
Median values for creatinine levels (IQR) (mg/mL) 0.009 (0.007-0.010) 0.030 (0.023-0.036) <0.001
Median values for metabolites of the KYN pathway (IQR) (µg/mL)
Tryptophan 10.70 (5.95-12.41) 10.76 (7.68-13.78) 0.7562
Kynurenine 0.65 (0.41-0.85) 0.96 (0.52-1.33) 0.0117
Kynurenic acid 0.007 (0.005-0.013) 0.028 (0.017-0.036) <0.001
Quinolinic acid 0.15 (0.10-0.27) 0.55 (0.42-0.78) <0.001
Urine
Median values for creatinine levels (IQR) (mg/mL) 0.658 (0.575-1.002) 0.540 (0.424-0.687) 0.0727
Median values for metabolites of the KYN pathway (IQR) (µg/mL)
Tryptophan 14.19 (7.52-25.31) 5.53 (3.28-13.20) 0.0071
Kynurenine 2.24 (0.97-2.97) 0.68 (0.35-2.26) 0.0547
Kynurenic acid 3.31 (2.01-3.90) 3.27 (1.83-4.46) 0.8766
Quinolinic acid 13.33 (10.21-19.41) 10.71 (5.94-21.89) 0.4151
Median values for renal fractional excretion of metabolites (%)
Tryptophan 1.8 (0.94-2.8) 3.3 (1.8-7.8) 0.0135
Kynurenine 3.2 (1.6-5.5) 4.5 (2.9-10.7) 0.1511
Kynurenic acid 439.6 (335.4-566.3) 519.2 (339.2-804.7) 0.2523
Quinolinic acid 104.4 (78.0-125.9) 98.9 (90.3-153.3) 0.6554
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aNteCeDeNCe oF INCReaSeD 
Kp aCtIVIty RelatIVe to 
tHe DeVelopMeNt oF 
aClF-RelateD INFeCtIoUS 
CoMplICatIoNS
As expected,(17) a high proportion (56%) of the 108 
patients who had ACLF but no infection at enroll-
ment subsequently developed bacterial infection during 
the 28-day follow-up. Of note, none of the baseline 
characteristics obtained at bedside with the exception 
of serum albumin could predict the development of 
bacterial infection (Supporting Table S6). In contrast, 
at baseline, several “bench” values assessing SI inten-
sity were higher in patients who developed infection 
during follow-up than in those who did not develop 
this complication (Fig. 3A, Table 4). Moreover, sig-
nificantly higher baseline levels of signals for immune 
suppression (i.e., interleukin [IL]-10 [Fig. 3B] and 
sMR/sCD206) were detected. Among the variety 
of SI markers evaluated at baseline, only IL-10 and 
sMR/sCD206 were independently associated with fol-
low-up bacterial infections in patients with ACLF who 
were “uninfected” at enrollment (odds ratio [95% con-
fidence interval (CI)]): Log (IL-10), 1.35 (1.04-1.73), 
P = 0.022; Log (sMR/sCD206), 2.80 (1.13-6.90), 
P  = 0.026). The area under receiver operating character-
istic curves for predicting the development of infection 
was 0.695 (95% CI, 0.595-0.796) for IL-10 and 0.679 
(95% CI, 0.575-0.784) for sMR/sCD206. In addition, 
the combination of these two markers of immunosup-
pression (−0.083 + 0.296 ln[IL-10] + 1.028 ln[sMR/
sCD206]) significantly predicted the risk of bacterial 
infections (Fig. 3C). Together these findings support 
the existence of immune suppression in patients with 
ACLF, providing a rational explanation for the high risk 
of developing bacterial infection in these patients.(17) 
Because KP activation can cause immune suppres-
sion through different mechanisms,(21) we compared, 
among patients with ACLF and no infection at enroll-
ment, the baseline levels of KP metabolites of patients 
who developed infection during follow-up with those 
taBle 3. Metabolites of the Kp at enrollment and last Follow-Up assessment among groups of patients Who Differed in 
their Clinical Course (Improvement, Worsening, Steady State)
Patient Groups n Enrollment Last Assessment P Value
Median values for Trp levels (IQR) (a.u. correspond to peak area/5  × 10 4) 
Improvement of ACLF 69 395 (251-507) 397 (291-509) 0.560
ACLF steady course 48 355 (235-473) 354 (216-547) 0.952
Worsening of AD or ACLF 46 330 (228-492) 369 (244-569) 0.307
AD steady course 95 379 (272-634) 430 (291-645) 0.258
Median values for KYN levels (IQR) (a.u. correspond to peak area/5  × 10 4) 
Improvement of ACLF 69 12.5 (6.1-29.1) 10.8 (6.5-23.5) 0.412
ACLF steady course 48 17.7 (9.8-32.8) 14.0 (8.3-22.9) 0.058
Worsening of AD or ACLF 46 13.5 (7.3-27.6) 13.9 (8.1-18.0) 0.203
AD steady course 95 9.8 (5.2-17.4) 8.7 (5.3-15.3) 0.543
Median values for the KYN to Trp ratio (IQR) 
Improvement of ACLF 69 0.031 (0.020-0.064) 0.029 (0.017-0.067) 0.372
ACLF steady course 48 0.048 (0.024-0.117) 0.045 (0.015-0.091) 0.214
Worsening of AD or ACLF 46 0.043 (0.020-0.093) 0.032 (0.024-0.066) 0.081
AD steady course 95 0.021 (0.012-0.054) 0.019 (0.012-0.037) 0.096
Median values for KA levels (IQR) (a.u. correspond to peak area/5  × 10 4) 
Improvement of ACLF 69 1.60 (0.93-2.84) 0.84 (0.48-1.47) <0.001
ACLF steady course 48 5.37 (1.90-10.39) 3.62 (1.05-18.28) 0.310
Worsening of AD or ACLF 46 1.63 (0.88-2.94) 2.36 (1.15-4.68) 0.009
AD steady course 95 0.77 (0.49-1.13) 0.64 (0.45-0.97) 0.509
Median values for QA levels (IQR) (a.u. correspond to peak area/5  × 10 4) 
Improvement of ACLF 69 60.5 (29.9-120.2) 43.7 (22.6-79.9) <0.001
ACLF steady course 48 127.3 (50.7-272.5) 104.8 (48.4-246.8) 0.896
Worsening of AD or ACLF 46 53.9 (25.0-117.7) 89.0 (49.9-159.1) 0.023
AD steady course 95 22.7 (16.4-45.2) 27.5 (15.8-43.1) 0.126
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patients who did not develop this complication. Thus, 
serum QA levels were higher in patients who developed 
infections during follow-up (Table 4), indicating that 
among patients with ACLF, an increase in KP activity 
precedes the onset of nosocomial bacterial infection.
Kp oVeRaCtIVIty IS aN 
INDepeNDeNt pReDICtoR oF 
SURVIVal IN CIRRHoSIS
Based on results of univariate analysis (Supporting 
Tables S7 and S8), multivariate analysis identified 11 
independent baseline predictors of 90-day mortality 
in the whole series of patients (Table 5). Among these 
predictors, there were only four variables obtained at 
bedside, including older age, higher bilirubin, higher 
international normalized ratio, and lower serum 
sodium and 7 “bench” variables, including higher lev-
els of KYN, IL-8, endothelial growth factor, vascu-
lar endothelial growth factor, and sMR/sCD206, and 
lower levels of Trp and INFγ. Based on results of the 
univariate analysis (Supporting Tables S9 and S10), 
we identified four independent baseline predictors of 
28-day mortality in patients with ACLF: older age, 
higher bilirubin, higher KYN, and higher sCD163 
(Table 5). Together, these findings indicate that 
increased KP activity is a major predictor of poor out-
come in patients with AD and in those with ACLF.
FIg. 3. (A) Differential baseline patterns of inf lammatory mediators/markers and metabolites of the KP in ACLF patients who did 
or did not develop follow-up bacterial infections. The pattern identifies higher markers of SI, immunosuppression (sMR/sCD206 and 
IL-10), and KP activity in patients who developed infections during FU. (B) Individual baseline values of IL-10 in ACLF patients who 
did or did not develop follow-up bacterial infections (values represented in quadratic scale). **P  < 0.001. (C) Accuracy of combining 
the baseline plasma levels of IL-10 and sMR/sCD206 in predicting 28-day follow-up bacterial infections in “uninfected” patients with 
ACLF. Abbreviations: AUROC, area under the receiver operating characteristic curve; FU, follow-up.
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Discussion
There are several investigations showing activa-
tion of KP in plasma, cerebrospinal fluid and brain 
tissue in primary biliary cirrhosis, HCV-associated 
chronic hepatitis, cirrhosis, hepatocellular carcinoma, 
and hepatic encephalopathy.(22-25) Our study is a pro-
spective observational investigation to assess Trp deg-
radation through the KP in a large series of patients 
with cirrhosis at different stages of the disease and its 
taBle 4. plasma Cytokines, Biomarkers of Macrophage activity and Systemic Inflammation, and Kp Metabolites in patients 
With aClF, Without Infection at enrollment, Who Did and Did Not Develop Infection During 28-Day Follow-up
Bacterial Infection During Follow-up
P Value
Absent Present
n = 47 n = 61
Median values for cytokines (IQR) (pg/mL)
Proinflammatory cytokines
TNFα 25.3 (14.9-36.0) 30.3 (17.7-41.8) 0.076
IL-6 25.2 (9.4-42.9) 34.0 (13.8-103.8) 0.015
IL-8 71.2 (32.5-204.6) 89.3 (50.5-149.5) 0.315
MCP-1 396.7 (261.9-572.3) 440.6 (348.6-629.5) 0.109
IP-10 1021.0 (596.4-1571.0) 1457.0 (735.3-2265.0) 0.017
MIP-1β 23.3 (12.9-37.0) 24.8 (17.9-54.8) 0.296
G-CSF 20.5 (11.7-40.7) 33.1 (11.1-70.5) 0.188
GM-CSF 5.1 (2.4-8.0) 6.2 (3.8-16.0) 0.081
Anti-inflammatory cytokines
IL-10 1.7 (1.0-8.2) 7.7 (2.0-34.0) 0.001
IL-1ra 13.5 (6.5-30.6) 19.4 (8.4-49.4) 0.105
Other cytokines
IFNγ 5.9 (1.7-24.4) 5.1 (2.2-17.1) 0.865
IFNα2 10.8 (2.9-32.2) 23.4 (8.0-52.9) 0.041
Eotaxin 115.1 (77.2-179.9) 122.3 (90.4-167.7) 0.401
IL-17A 3.1 (1.3-13.6) 3.0 (1.4-15.6) 0.568
IL-7 2.4 (1.4-5.2) 2.1 (1.4-7.5) 0.795
EGF 3.2 (2.8-21.4) 6.9 (2.8-27.4) 0.205
VEGF 62.0 (26.3-196.3) 44.0 (26.3-150.7) 0.990
Median values for irreversibly oxidized albumin fraction (IQR) (%)
HNA2 8.3 (5.0-12.4) 11.2 (7.0-16.5) 0.075
Median values for markers of macrophage activation (IQR) (mg/L)
sCD163 9.4 (5.4-15.5) 14.2 (8.2-19.2) 0.011
sMR/sCD206 0.7 (0.6-1.1) 1.1 (0.8-1.5) 0.002
Median values for markers of systemic inflammation (IQR)
White cell count (× 109 cells/L) 8.2 (5.2-12.2) 7.4 (5.6-13.4) 0.902
C-reactive protein concentration (mg/L) 19.0 (9.3-43.0) 27.0 (14.1-52.3) 0.141
Median values for metabolites of the KP (IQR) (a.u. correspond to peak area/5 × 104)
Trp 345 (200-456) 414 (278-509) 0.069
KYN 19.0 (7.9-39.3) 17.9 (11.2-32.6) 0.848
KYN/Trp ratio 0.055 (0.023-0.119) 0.044 (0.024-0.090) 0.701
KA 1.71 (0.67-5.27) 2.50 (1.12-5.23) 0.080
QA 67.2 (25.3-127.0) 102.3 (41.8-206.4) 0.037
Abbreviations: EGF, epidermal growth factor; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage 
colony-stimulating factor; IL-1ra, interleukin-1 receptor antagonist protein; IP-10, 10 kDa interferon gamma-induced protein; MCP-
1, monocyte chemotactic protein 1; MIP-1ß, macrophage inf lammatory protein 1-beta; VEGF, vascular endothelial growth factor.
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relationship with the severity of the disease, clinical 
course, and survival. We report six important findings. 
First, KP activity was normal in patients with compen-
sated cirrhosis but markedly increased in patients with 
AD and particularly in those with ACLF. Second, our 
results were consistent with activation of KP as a result 
of SI. Third, KP activity and overall severity of cir-
rhosis followed similar orchestration. Indeed, among 
patients with AD, KP activity was higher in patients 
with KD or BD than in those without these dysfunc-
tions. Among patients with ACLF, KP activity was 
remarkably higher in patients with ACLF-KF than 
in patients with KF-free ACLF. Fourth, we found an 
antecedence of increased KP activity relative to the 
development of ACLF. Fifth, we observed an ante-
cedence of KP overactivity relative to ACLF-related 
infectious complications. Finally, higher KP activity 
was an independent predictor of death in patients with 
AD (at 90 days) and in those with ACLF (at 28 days).
The first issue to be discussed is the strong asso-
ciation between KF and high circulating levels of 
Trp-KYN derivatives in patients with ACLF, which 
has been proposed to be related to a reduction in the 
renal excretion of Trp-KYN derivatives and not to the 
mechanism of kidney failure. Our data do not support 
this contention. Indeed, the urinary concentration 
of KYN, KA, and QA were similar in our patients 
with KF-free ACLF and in those with ACLF-KF 
despite marked differences in serum concentrations of 
Trp-KYN derivatives. Moreover, the fractional excre-
tion of KYN, KA and QA, which estimates the per-
centage of the filtered Trp-KYN derivatives excreted 
by the urine, were also similar between groups. 
Therefore, the difference in the levels of circulating 
Trp-KYN derivatives between patients with ACLF 
and KF and those without KF cannot be explained 
by differences in the renal excretion of Trp-KYN 
derivatives.
The heterogeneity of urine Trp-KYN derivative 
profiles in patients with ACLF was a key observation 
that may help to understand the potential mechanism 
of the extremely higher activation of the KP associ-
ated with ACLF-KF relative to KF-free ACLF, the 
absence of differences between the urine levels of the 
Trp-KYN derivatives in both conditions, the mech-
anism of the specific urine profile of each Trp-KYN 
derivative, and the pathogenesis of the marked activa-
tion of the renal KP in patients with ACLF-KF.
Whereas the urine-to-serum ratios for KA con-
centrations were strikingly increased in both groups 
of patients with ACLF, the increases in ratios for QA 
concentrations, although important, were significantly 
less marked, and the increases in ratios for KYN 
concentrations were either mild or inexistent. These 
differences in the urine-to-serum ratios between Trp-
KYN derivatives were poorly related with glomeru-
lar filtration rate (as estimated by serum creatinine) 
and their corresponding serum levels. Together, these 
taBle 5. Independent Baseline predictors of 90-Day Mortality in the Whole Series of patients and 28-Day Mortality in 
patients With aClF
Variable
Whole Series of Patients Patients With ACLF
HR for Death at 90 days (95% CI) P Value HR for Death at 28 days (95% CI) P Value
Ln(Trp) 0.71 (0.53-0.97) 0.029 —
Ln(KYN) 1.36 (1.14-1.62) <0.001 1.66 (1.29-2.15) <0.001
Ln(IL-8) 1.26 (1.00-1.58) 0.047 —
Ln(IFNγ) 0.82 (0.71-0.95) 0.008 —
Ln(EGF) 0.85 (0.72-0.99) 0.041 —
Ln(VEGF) 1.29 (1.10-1.51) 0.001 —
Age 1.04 (1.02-1.06) <0.001 1.06 (1.03-1.09) <0.001
Ln(Bilirubin) 1.32 (1.04-1.70) 0.025 1.77 (1.23-2.56) 0.002
Ln(INR) 2.90 (1.62-5.18) <0.001 —
Ln(sCD163) — 2.07 (1.12-3.83) 0.020
Ln(sMR/sCD206) 2.36 (1.42-3.91) <0.001 —
Serum sodium 0.96 (0.93-1.00) 0.033 —
Abbreviations: EGF, epidermal growth factor; HR, hazard ratio; INR, international normalized ratio; Ln, natural logarithm; VEGF, 
vascular endothelial growth factor.
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findings strongly suggest a tubular mechanism (e.g., 
tubular secretion) that is unrelated to renal dysfunc-
tion as the most likely explanation for high urine-to-
serum ratios of some Trp-KYN metabolites, but not 
all.
The renal tubular cells are among the most sen-
sitive cells for expressing the Trp-consuming enzyme 
IDO in response to inflammatory cues.(26) Here, we 
found that the urine concentration of Trp was mark-
edly lower in patients with ACLF-KF than in those 
with KF-free ACLF, suggesting that Trp consump-
tion is related to higher degree of renal inflammation 
in the former group of patients. Therefore, it is likely 
that in patients with ACLF-KF, kidney inflammation 
could lead to increased tubular release of Trp-KYN 
derivatives into the urine and perhaps also to spillover 
in the systemic circulation. The differences in profile 
of Trp-KYN derivatives in serum and urine probably 
reflects differences in their origin (primarily the tubu-
lar cells in the urine and from many different types 
of cells, including the tubular cells, in serum). The 
development of KF and associated tubular release of 
Trp-KYN derivatives would depend on the severity 
of renal inflammation. This feature was detected in 
serum, but not in urine, probably because the severity 
of renal failure impairs the mechanisms influencing 
the tubular release of endogenous metabolites, espe-
cially the tubular urine flow rate.
Kynurenines have deleterious effects on brain 
function and participate in the pathogenesis of a 
variety of acute and chronic brain disorders and dis-
eases associated with SI.(13,27) Because the expression 
of IDO in the brain is low, tissue concentration of 
kynurenines depends largely on the transport of circu-
lating kynurenines across the BBB. KYN and 3-HK, 
but not KA and QA, are readily transported across the 
BBB. Once in the brain, they are further degraded to 
produce KA and QA and other kynurenines. QA and, 
with less intensity, 3-HK and 3-HAA have neuro-
toxic effects due to their capacity to generate reactive 
oxygen species. QA also causes neuronal excitotoxicity 
through the activation of NMDA (glutamate) recep-
tors. The ultimate consequences of these mechanisms 
are brain inflammation and oxidative stress, changes 
in neurotransmission, and neuronal dysfunction and 
apoptosis.
There is evidence from both clinical and experi-
mental studies that brain inflammation and hyper-
ammonemia are major mechanisms of hepatic 
encephalopathy.(28) There are some preliminary data 
suggesting that activated KP may also play a contrib-
utory role. Two-fold to 10-fold elevations of cerebro-
spinal fluid QA concentrations have been reported in 
4 neonates with hepatic coma and in 6 patients with 
cirrhosis who died with hepatic encephalopathy.(24,25) 
The cortical content of QA was also 3 times higher 
in the latest group of patients than in a control group 
of patients with cirrhosis dying from other causes. In 
addition, high levels of KYN in cerebrospinal fluid 
and plasma have recently been reported in patients 
with cirrhosis and hepatic encephalopathy. Our data 
showing a close association between high KP activ-
ity and the presence of BD and BF in patients with 
AD and ACLF, respectively, are in keeping with 
this suggestion. The neurotoxic effects of QA and 
other kynurenines could also explain the surpris-
ingly extended areas of gray and white matter losses 
described in patients with decompensated cirrhosis.(5)
KYN has been identified as an endothelium-de-
rived relaxing factor, the release of which is promoted 
by the effect of the inflammatory mediators on IDO, 
leading to activation of soluble guanylyl cyclase in the 
underlying arteriolar smooth muscle cells and vasodi-
lation.(29) Inhibition of IDO activity protects animals 
with sepsis from hypotension, indicating that KP is 
a major contributory mechanism of systemic circula-
tory dysfunction in SI.(30) Our results suggest that this 
may also be the case in patients with cirrhosis with 
AD and ACLF, as the circulating levels of QA and 
other kynurenines correlated directly with the degree 
of systemic circulatory dysfunction. Angiotensin II 
also increases the expression of IDO, activates the 
KP, and promotes oxidative stress and apoptosis in 
endothelial cells.(30) This mechanism may be import-
ant in patients with cirrhosis with ACLF, because 
the renin-angiotensin system is markedly activated in 
these patients. Therefore, the sequential occurrence 
of acute and severe SI, increased endothelial IDO 
and KP activity and oxidative stress, KYN mediated 
arteriolar vasodilation, homeostatic stimulation of the 
renin-angiotensin system, and further increase in the 
KP activity and oxidative stress represents a potential 
vicious pathophysiological circle that could lead to 
progressive endothelial cell apoptosis, microcirculatory 
dysfunction, and organ failure.
The KYN/Trp ratio and the plasma levels of 
kynurenines are accurate predictors of multiorgan fail-
ure and mortality in critically ill patients hospitalized 
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by acute BF of different etiologies,(31) severe trauma,(32) 
acute pancreatitis(33) and sepsis,(34) suggesting that KP 
activity is a critical determinant in the evolution of 
diseases associated with acute SI. In fact, the blockade 
of the two key enzymes of the KP, IDO, and KMO 
reduces the rate of multiorgan failure and mortality in 
experimental sepsis or acute pancreatitis.(30,35,36) Our 
results indicate that the course of ACLF correlated 
closely with changes in plasma KA, QA, and Trp con-
centrations, and that kynurenines were independent 
predictors of mortality both in patients with AD and 
with ACLF. This supports the idea that KP activity 
might be an important mechanism of multiorgan fail-
ure and mortality in cirrhosis.
Fernández et al. recently showed that patients 
hospitalized with ACLF not triggered by infections 
are highly predisposed to develop nosocomial infec-
tions, suggesting immune paralysis.(17) Our data sup-
port this contention, as the higher circulating levels 
of IL-10 and sMR/sCD206 in patients with ACLF 
were the only independent predictors of nosocomial 
infections in these patients. The activation of IDO is 
a potent immunosuppressive mechanism(10,37,38) and 
increases IL-10 release. Because the baseline values of 
KP activity were also higher in patients with ACLF 
developing nosocomial infections than in those who 
did not develop infections, our data might indicate 
that kynurenines contribute to the immunosuppres-
sion present in patients with ACLF.
Our study has two important limitations. First, it 
is an observational investigation looking into asso-
ciations between KP activity and patients’ charac-
teristics or clinical course, and although significant 
associations may be suggestive, they do not ensure 
cause-to-effect relationships. Second, some active KP 
derivatives were not detectable using our untargeted 
metabolomics workflow (essentially due to sensitivity 
limitations), and our data are discussed in terms of 
KP activity rather than specific Trp-KYN derivatives.
In summary, we show that KP is activated in 
patients with AD, especially in those with ACLF, 
likely as a result of SI and secondary activation of 
IDO enzymes. We also observed close associations 
between the KP activity and the presence and/or 
development of kidney and brain dysfunction/failure, 
ACLF, impairment in systemic circulatory function, 
nosocomial bacterial infections, and mortality. Trp-
KYN derivatives, which are known to have neuro-
toxic, pro-oxidant, immunosuppressive, endothelial 
dysfunctional and pro-apoptotic properties, could play 
an active role in these associations.
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